Pharma Turmoil: Trump's Drug Tariff Orders Shake Industry

In a bold move, President Donald Trump signed an executive order introducing hefty 100% tariffs on branded pharmaceuticals unless drug manufacturers agree to government drug pricing deals or move production to the United States. This decision is part of an aggressive policy to domesticate drug production and control escalating drug prices.

Meanwhile, the complex international pharmaceutical trade is seeing additional turmoil. A Belgian court has mandated that Poland and Romania honor vaccine purchase contracts with Pfizer, pushing the countries to comply with previous agreements or face legal and financial consequences.

In domestic developments, the FDA has released updates on its policies regarding the compounding of popular GLP-1 medications. As drug shortages ease, the FDA is tightening regulations, aiming to ensure that compounded drugs are produced only when commercially available options are scarce.